Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

This study tests a new type of CAR-T cell therapy (called Meta10-19) — where a patient's own immune cells are re-engineered to fight cancer — for people with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has relapsed or stopped responding to treatment. **You may be eligible if...** - You are an adult with confirmed relapsed or refractory DLBCL (including primary mediastinal large B-cell lymphoma or transformed follicular lymphoma) - You have received at least 2 prior treatment regimens including a chemotherapy containing anthracycline - Your cancer cells test positive for the CD19 protein - You are in good overall health (ECOG 0 or 1) with a life expectancy greater than 12 weeks **You may NOT be eligible if...** - You have a history of cancer spreading to the brain or spinal cord - You have previously had a donor stem cell transplant (allogeneic) - You have active hepatitis B, hepatitis C, or HIV - You have had a heart attack or severe heart disease within the last 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.